GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Kalbe Farma Tbk (ISX:KLBF) » Definitions » Piotroski F-Score

PT Kalbe Farma Tbk (ISX:KLBF) Piotroski F-Score : 6 (As of May. 05, 2024)


View and export this data going back to 1991. Start your Free Trial

What is PT Kalbe Farma Tbk Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Kalbe Farma Tbk has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for PT Kalbe Farma Tbk's Piotroski F-Score or its related term are showing as below:

ISX:KLBF' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 6

During the past 13 years, the highest Piotroski F-Score of PT Kalbe Farma Tbk was 7. The lowest was 3. And the median was 5.


PT Kalbe Farma Tbk Piotroski F-Score Historical Data

The historical data trend for PT Kalbe Farma Tbk's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Kalbe Farma Tbk Piotroski F-Score Chart

PT Kalbe Farma Tbk Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 7.00 4.00 6.00

PT Kalbe Farma Tbk Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 4.00 4.00 6.00

Competitive Comparison of PT Kalbe Farma Tbk's Piotroski F-Score

For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Kalbe Farma Tbk's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PT Kalbe Farma Tbk's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 855717.045 + 673280.141 + 535928.423 + 701822.431 = Rp2,766,748 Mil.
Cash Flow from Operations was 199521.194 + 336087.816 + 942425.684 + 1429440.477 = Rp2,907,475 Mil.
Revenue was 7869160.883 + 7309768.476 + 7382077.055 + 7888127.664 = Rp30,449,134 Mil.
Gross Profit was 3219251.245 + 2956347.52 + 2731202.594 + 2916444.175 = Rp11,823,246 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(27241313.026 + 28239682.359 + 27419566.534 + 27181763.267 + 27057568.182) / 5 = Rp27427978.6736 Mil.
Total Assets at the begining of this year (Dec22) was Rp27,241,313 Mil.
Long-Term Debt & Capital Lease Obligation was Rp318,779 Mil.
Total Current Assets was Rp15,917,724 Mil.
Total Current Liabilities was Rp3,243,169 Mil.
Net Income was 834882.116 + 802066.548 + 848565.326 + 896695.779 = Rp3,382,210 Mil.

Revenue was 7015705.508 + 6858880.528 + 7307184.596 + 7751732.014 = Rp28,933,503 Mil.
Gross Profit was 2928787.617 + 2869403.834 + 2936366.214 + 2968709.439 = Rp11,703,267 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(25666635.156 + 26861580.834 + 25263347.747 + 26187153.771 + 27241313.026) / 5 = Rp26244006.1068 Mil.
Total Assets at the begining of last year (Dec21) was Rp25,666,635 Mil.
Long-Term Debt & Capital Lease Obligation was Rp311,899 Mil.
Total Current Assets was Rp16,710,230 Mil.
Total Current Liabilities was Rp4,431,038 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Kalbe Farma Tbk's current Net Income (TTM) was 2,766,748. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PT Kalbe Farma Tbk's current Cash Flow from Operations (TTM) was 2,907,475. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=2766748.04/27241313.026
=0.10156442

ROA (Last Year)=Net Income/Total Assets (Dec21)
=3382209.769/25666635.156
=0.13177457

PT Kalbe Farma Tbk's return on assets of this year was 0.10156442. PT Kalbe Farma Tbk's return on assets of last year was 0.13177457. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PT Kalbe Farma Tbk's current Net Income (TTM) was 2,766,748. PT Kalbe Farma Tbk's current Cash Flow from Operations (TTM) was 2,907,475. ==> 2,907,475 > 2,766,748 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=318778.924/27427978.6736
=0.0116224

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=311898.813/26244006.1068
=0.01188457

PT Kalbe Farma Tbk's gearing of this year was 0.0116224. PT Kalbe Farma Tbk's gearing of last year was 0.01188457. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=15917724.101/3243168.545
=4.90807797

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=16710229.57/4431038.46
=3.77117683

PT Kalbe Farma Tbk's current ratio of this year was 4.90807797. PT Kalbe Farma Tbk's current ratio of last year was 3.77117683. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PT Kalbe Farma Tbk's number of shares in issue this year was 46255.641. PT Kalbe Farma Tbk's number of shares in issue last year was 46515.941. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=11823245.534/30449134.078
=0.38829497

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11703267.104/28933502.646
=0.40448843

PT Kalbe Farma Tbk's gross margin of this year was 0.38829497. PT Kalbe Farma Tbk's gross margin of last year was 0.40448843. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=30449134.078/27241313.026
=1.11775574

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=28933502.646/25666635.156
=1.12728071

PT Kalbe Farma Tbk's asset turnover of this year was 1.11775574. PT Kalbe Farma Tbk's asset turnover of last year was 1.12728071. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PT Kalbe Farma Tbk has an F-score of 6 indicating the company's financial situation is typical for a stable company.

PT Kalbe Farma Tbk  (ISX:KLBF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PT Kalbe Farma Tbk Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of PT Kalbe Farma Tbk's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Kalbe Farma Tbk (ISX:KLBF) Business Description

Traded in Other Exchanges
Address
Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, Jakarta, IDN, 10510
Kalbe Farma is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. Majority of the company's gross profits are derived from the distribution and logistics segments. The company primarily operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.

PT Kalbe Farma Tbk (ISX:KLBF) Headlines

No Headlines